Revenue ₹1,422 Cr (+21% YoY)
3 met · 0 close · 14 missed across 17 tracked promises
View all executive profiles for Ajanta Pharma LimitedAjanta Pharma delivered a strong Q4 FY26 with revenue of INR 1,422 crore (+21% YoY) and PAT of INR 267 crore (+18% Yo...
18% promises delivered
Based on 17 tracked promises across 12 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Ajanta Pharma Limited has delivered on 18% of tracked promises, above the Nifty 50 average of ~12%.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
15 May 2026
Revenue ₹1,422 Cr (+21% YoY)
Ajanta Pharma delivered a strong Q4 FY26 with revenue of INR 1,422 crore (+21% YoY) and PAT of INR 267 crore (+18% YoY), driven by stellar US generics growth (+56% YoY...
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q3 FY26
14 Feb 2026
Revenue ₹1,375 Cr (+20% YoY)
Ajanta Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 1,375 crore (+20% YoY) and EBITDA of INR 382 crore (+19% YoY).
bullish
high
4 missed
Read full analysis →
Q2 FY26
07 Nov 2025
Revenue ₹1,354 Cr (+14% YoY)
Ajanta Pharma delivered a strong Q2 FY26 with revenue of INR 1,354 crore (+14% YoY) and PAT of INR 260 crore (+20% YoY).
bullish
high
2 met
Read full analysis →
Q1 FY26
01 Aug 2025
Revenue ₹1,303 Cr (+14% YoY)
Ajanta Pharma delivered a 14% revenue growth to INR 1,303 crore in Q1 FY26, driven by a 36% surge in US generics (INR 310 crore) and 16% India growth (INR 409 crore).
bullish
high
3 missed
Read full analysis →
Q4 FY25
15 May 2025
Revenue ₹1,170 Cr (+11% YoY)
Ajanta Pharma delivered a solid Q4 FY25 with consolidated revenue of INR 1,170 crore (+11% YoY) and PAT of INR 225 crore (+11% YoY).
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q3 FY25
10 Feb 2025
Revenue ₹1,146 Cr (+4% YoY)
Ajanta Pharma reported Q3 FY25 revenue of INR 1,146 crore (+4% YoY), with branded generics growing 10% to INR 834 crore.
bullish
high
2 missed
Read full analysis →
Q2 FY25
12 Nov 2024
Revenue ₹1,187 Cr (+15% YoY)
Ajanta Pharma delivered a solid Q2 FY25 with revenue of INR 1,187 crore (+15% YoY), driven by strong branded generics growth of 20% (Asia +28%, Africa +35%).
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q1 FY25
14 Aug 2024
Revenue ₹1,145 Cr (+12% YoY)
Ajanta Pharma delivered a strong Q1 FY25 with revenue of INR 1,145 crore (+12% YoY) and EBITDA of INR 330 crore (+22% YoY), driven by branded generics growth of 17%.
bullish
high
4 missed
Read full analysis →
Q4 FY24
14 May 2024
Revenue ₹1,054 Cr (+20% YoY)
Ajanta Pharma delivered a strong Q4 FY24 with revenue of INR 1,054 crore (+20% YoY), EBITDA of INR 278 crore (+86% YoY), and PAT of INR 203 crore (+66% YoY).
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q3 FY24
30 Jan 2024
Revenue ₹1,105 Cr (+14% YoY)
Ajanta Pharma reported a strong Q3 FY24 with consolidated revenue of INR 1,105 crore, up 14% YoY, driven by broad-based growth across branded generics.
bullish
high
1 met
Read full analysis →
Q2 FY24
10 Nov 2023
Revenue ₹1,028 Cr (+10% YoY)
Ajanta Pharma delivered a solid Q2 FY24 with consolidated revenue of INR 1,028 crore (+10% YoY) and EBITDA of INR 291 crore (+48% YoY), driven by strong US generics gr...
bullish
high
1 missed
Read full analysis →
Q1 FY24
14 Jul 2023
Revenue ₹1,021 Cr (+7% YoY)
Ajanta Pharma reported a solid Q1 FY24 with consolidated revenue of ₹1,021 crore (+7% YoY) and EBITDA margin of 26% (+300 bps YoY), driven by gross margin expansion fr...
bullish
high
Scorecard starts after historical backfill
Read full analysis →